Evidence map›Paper›PMID 36962996›Full record

ArticlePLOS global public health2023

Antiretroviral treatment failure and associated factors among people living with HIV on therapy in Homa Bay, Kenya: A retrospective study.

Rose Masaba, Godfrey Woelk, Stephen Siamba, James Ndimbii, Millicent Ouma, Jacob Khaoya, Abraham Kipchirchir, Boniface Ochanda, Gordon Okomo

Open access · goldFull text read
In one paragraph

Article in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rose MasabaElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.ORCID https://orcid.org/0000-0003-1801-7938
Godfrey WoelkElizabeth Glaser Pediatric AIDS Foundation, Washington, D.C., United States of America.ORCID https://orcid.org/0000-0002-8382-0893
Stephen SiambaElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.
James NdimbiiElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.
Millicent OumaElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.
Jacob KhaoyaElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.
Abraham KipchirchirElizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.
Boniface OchandaDivision of Global HIV & TB, Center for Global Health, US Centers for Disease Control and Prevention Kenya, Kisumu, Kenya.
Gordon OkomoMinistry of Health, Homa Bay County, Kenya.
Centers for Disease Control and Prevention · KEElizabeth Glaser Pediatric AIDS Foundation · USMinistry of Health · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite large numbers of patients accessing antiretroviral treatment (ART) in Kenya, few studies have explored factors associated with virologic failure in Western Kenya, specifically. We undertook a study in Homa Bay County, Kenya to assess the extent of virologic treatment failure and factors associated with it. This was an observational retrospective study conducted from September 2020 to January 2021. Data were abstracted from the records of patients who had been on ART for at least six months at the time of data collection after systematic sampling stratified by age group at ART initiation (0-14 and 15+ years), using probability proportion to the numbers of patients attending the facility. Confirmed viral treatment failure was defined as viral load ≥1000 copies/ml based on two consecutive viral load measurements after at least three months of enhanced adherence counseling. Data were analyzed using descriptive statistics and Cox regression modeling. Of the 2,007 patients sampled, 160 (8.0%) had confirmed virologic treatment failure. Significantly higher virologic treatment failure rates were identified among male patients 78/830 (9.4%) and children 115/782 (14.7%). Factors associated with virologic treatment failure (VTF), were age 0-14 years, adjusted hazard ratio (AHR) 4.42, (95% Confidence Interval [CI], 3.12, 6.32), experience of treatment side effects AHD: 2.43, (95% CI, 1.76, 3.37), attending level 2/3 health facility, AHR: 1.87, (95% CI: 1.29, 2,72), and history of opportunistic infections (OIs), AHR: 1.81, (95% CI, 1.76, 3.37). Children, attendees of level 2/3 health facilities, patients with a history of OIs, and those experiencing treatment side-effects are at risk of VTF. Increased focus on children and adolescents on screening for drug resistance, administration of and adherence to medication, and on effective information and education on side-effects is critical. Additionally, there is need for increased training and support for health care workers at primary level care facilities.

Identifiers

PMID36962996
PMCPMC10021395
OpenAlexW4322765149

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read105
identifiers read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.